Editor - Mark Hylton Sutherland | University of Bradford | 19724
ISSN: 2475-3173

Cervical Cancer: Open Access
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Mark Hylton Sutherland

Mark Hylton Sutherland
Mark Hylton Sutherland Molecular Pharmacology Institute of Cancer Therapeutics University of Bradford UK
University of Bradford


 Dr Mark Sutherland is a Senior Experimental Officer at the Institute of Cancer Therapeutics, University of Bradford. After completing his MSc in Molecular Biology at the University of Stellenbosch, South Africa he worked for a few years as a school teacher and University Lecturer. He was offered a PhD at the Charite – Campus Benjamin Franklin, Berlin, Germany where he received his degree. He then worked for a number of years as a PDRA in Berlin in the field of immunotoxins. In 2005 he moved to the University of Bradford. In his current role he carries out research for a number a projects within the Institute, teach laboratory skills to MSc and PhD students, and lectures undergraduate and MSc students. His current research is in the field of integrins as a target for new anti-cancer drugs in prostate cancer and melanoma, as well as the role of sialyltransferases in neuroblastoma.

Research Interest


Dual/multi-integrin antagonism in prostate cancer and melanoma

Polysialyltransferase (the tumour cell glycocalyx as a therapeutic target) in neuroblastoma



Global Speakers in the subject

Global Experts in the subject

Relevant Topics